VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Taysha Gene Therapies, Inc. (TSHA) Total Return Calculator with Dividends Reinvested

Taysha Gene Therapies, Inc.

Popular:

The total return for Taysha Gene Therapies, Inc. (TSHA) stock is +251.05% over the past 12 months. So far it's up 27.05% this year. The 5-year total return is -68.54%, meaning $10,000 invested in TSHA stock 5 years ago would be worth $3,146 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in TSHA 1 year ago, it would be worth $31,762 today — you'd have gained $21,762.

With Dividends Reinvested$31,762+217.62%

Price Only (No DRIP)$31,762+217.62%

Period2025-05-08 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in TSHA

1Y$35,105+$25,105 (+251.1%)251.1% CAGR

3Y$93,944+$83,944 (+839.4%)111.0% CAGR

5Y$3,146-$6,854 (-68.5%)-20.6% CAGR

10Y$2,772-$7,228 (-72.3%)-12.0% CAGR

15Y$2,772-$7,228 (-72.3%)-8.2% CAGR

20Y$2,772-$7,228 (-72.3%)-6.2% CAGR

30Y$2,772-$7,228 (-72.3%)-4.2% CAGR

Taysha Gene Therapies, Inc. did not pay dividends during this period. Total return = price return.

Loading TSHA total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+27.05%	—	+27.05%	—	$12,705
1Y	+251.05%	251.05%	+251.05%	—	$35,105
3Y	+839.44%	111.00%	+839.44%	—	$93,944
5Y	-68.54%	-20.65%	-68.54%	—	$3,146
10Y	-72.28%	-12.04%	-72.28%	—	$2,772
15Y	-72.28%	-8.20%	-72.28%	—	$2,772
20Y	-72.28%	-6.21%	-72.28%	—	$2,772
30Y	-72.28%	-4.19%	-72.28%	—	$2,772

Risk & Highlights

Best Year+197.30%2025

Worst Year-80.94%2022

Max Drawdown-31.13%2025-12-24 → 2026-03-27 · Recovered 2026-04-15

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-13.71%	-13.71%	—	+0.41%	-14.1pp
2025	+197.30%	+197.30%	—	+16.64%	+180.7pp
2024	+1.17%	+1.17%	—	+24.00%	-22.8pp
2023	-19.55%	-19.55%	—	+24.81%	-44.4pp
2022	-80.94%	-80.94%	—	-19.95%	-61.0pp

TSHA outperformed the S&P 500 by 220.68pp over the past year (+251.05% vs +30.37%).

Loading summary...

TSHA Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
TSHATaysha Gene Therapies, Inc.	$1.9B	+46.0%	+27.0%	+251.1%	—	+839.4%	-68.5%	-72.3%
SRPTSarepta Therapeutics, Inc.	$2.2B	-9.9%	-2.4%	-43.4%	—	-83.6%	-72.1%	+18.0%
RAREUltragenyx Pharmaceutical Inc.	$2.6B	+12.9%	+10.7%	-21.8%	—	-44.5%	-77.2%	-59.4%
FOLDAmicus Therapeutics, Inc.	$4.5B	+0.1%	+1.5%	+137.9%	—	+19.0%	+48.6%	+119.2%
ARWRArrowhead Pharmaceuticals, Inc.	$10.9B	+27.4%	+15.0%	+496.9%	—	+92.7%	+17.4%	+1253.3%
RCKTRocket Pharmaceuticals, Inc.	$398M	+5.5%	+6.1%	-45.2%	—	-82.8%	-91.6%	-91.3%
SGMOSangamo Therapeutics, Inc.	$22M	-60.5%	-77.0%	-84.4%	—	-92.0%	-99.0%	-98.4%
CRSPCRISPR Therapeutics AG	$5.1B	+5.5%	-2.5%	+53.1%	—	-6.3%	-51.3%	+272.0%
EDITEditas Medicine, Inc.	$297M	+10.6%	+47.8%	+127.8%	—	-68.5%	-91.1%	-90.0%
BEAMBeam Therapeutics Inc.	$3.2B	+28.5%	+16.0%	+93.9%	—	-5.6%	-55.6%	+67.8%
NTLAIntellia Therapeutics, Inc.	$1.6B	+1.2%	+48.9%	+88.1%	—	-68.3%	-79.8%	-42.9%

Compare:TSHA vs SRPT TSHA vs RARE TSHA vs FOLD TSHA vs SRPT vs RARE

About TSHA Dividend Returns

Taysha Gene Therapies, Inc. (TSHA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of TSHA over the past year?

Taysha Gene Therapies, Inc. (TSHA) delivered a return of 251.05% over the past year. Since TSHA does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in TSHA be worth today?

A $10,000 investment in Taysha Gene Therapies, Inc. one year ago would be worth $35,105 today, representing a gain of $25,105.

Q3Does TSHA pay dividends?

Taysha Gene Therapies, Inc. (TSHA) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For TSHA, the total return equals the price-only return.

Q4Did TSHA beat the S&P 500?

Yes, Taysha Gene Therapies, Inc. (TSHA) outperformed the S&P 500 by 220.68 percentage points over the past year. TSHA delivered a total return of 251.05%, compared to the S&P 500's 30.37%. This 220.68pp alpha means investors in TSHA earned more than a passive S&P 500 index fund.

Q5What is TSHA's worst drawdown?

Taysha Gene Therapies, Inc. (TSHA) experienced a maximum drawdown of -31.13% over the past year, declining from its peak on 2025-12-24 to its trough on 2026-03-27. The stock recovered to its prior peak by 2026-04-15. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is TSHA's long-term total return over 10, 20, or 30 years?

Here are Taysha Gene Therapies, Inc. (TSHA)'s long-term returns with dividends reinvested. Over 10 years, the total return is -72.3% (-12.0% CAGR) — $10,000 would have grown to $2,772. Over 20 years: -72.3% total return (-6.2% CAGR) — $10,000 → $2,772. Over 30 years: -72.3% total return (-4.2% CAGR) — $10,000 → $2,772. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was TSHA's best and worst year?

Taysha Gene Therapies, Inc.'s best calendar year was 2025 with a total return of 197.3%. Its worst year was 2022 with a total return of -80.9%. This range shows the volatility investors should expect — the difference between the best and worst year is 278.2 percentage points.